

RAVULIZUMAB (Ultomiris) Infusion Order Form

Original ordering provider must be enrolled in REMS program <https://www.ultsolrems.com/>

Weight: _____ kg Height: _____ inches [] New treatment [] Transfer – next due _____

PRIOR TO FIRST DOSE: Verify meningococcal vaccine completed at least 14 days prior to start date.

Note: Do not use combined ABCWY vaccine as full immune effect delayed for 6 months.

*Document dates booster dose due in clinic record.

- Meningococcal conjugate (MenACWY) vaccine

0.5 ml IM x 2 doses at least 8 weeks apart

Booster 0.5 ml IM x1 every 5 years.*

Date complete _____

- Meningococcal group B (MenB) vaccine

0.5 ml IM x 2 doses at least 4 weeks apart

Booster 0.5 ml IM once year after series complete, then every 2 to 3 years.*

Date complete _____

If less than 2 weeks since full meningococcal vaccination, verify patient is on prophylactic anti-infective for the first 2 weeks of therapy. Consider antimicrobial prophylaxis with oral antibiotics for the duration of therapy.

Antimicrobial therapy ordered if any: _____

PRIOR TO EACH INFUSION: See page 2 for labs, nursing assessment, vital signs, administration and observation times. Pharmacy to verify registration of ordering provider with UltSolREMS.

PRE-MEDICATE (30 minutes before infusion):

[] loratadine 10 mg PO

[] acetaminophen _____ mg PO

[] diphenhydramine _____ mg PO

[] methylprednisolone _____ mg IV

[] diphenhydramine _____ mg IV

DOSE (select diagnosis and weight range): Administer within 7 days of the recommended interval.

Loading dose(LD) IV once. Maintenance dose (MD) IV every 8 weeks, starting 2 weeks after loading dose.

✓	Diagnosis (Check one)	Weight:	<input type="checkbox"/> 20 to <30 kg	<input type="checkbox"/> 30 to < 40 kg	<input type="checkbox"/> 40 to < 60 kg	<input type="checkbox"/> 60 to < 100 kg	<input type="checkbox"/> ≥100 kgs
	Myasthenia gravis <i>AChR positive</i>				LD: 2400 mg then MD: 3000 mg	LD: 2700 mg then MD: 3300 mg	LD: 3000 mg then MD: 3600 mg
	Neuromyelitis optica						
	Atypical hemolytic uremic syndrome		LD: 900 mg then MD: 2100 mg	LD: 1200 mg then MD: 2700 mg	LD: 2400 mg then MD: 3000 mg	LD: 2700 mg then MD: 3300 mg	LD: 3000 mg then MD: 3600 mg
	Paroxysmal nocturnal hemoglobinuria						

[] Other: _____

REQUIRED Prior Authorization Number: _____ [] pending [] complete [] not needed*

*If not needed is chosen, date, time and name of person at health insurer who authorized.

Date: _____ Time: _____ Duration of authorization: _____

Checklist for non-RFGH credentialed providers:

[] Problem list, current medication and allergies attached

[] Provider to provider communication is required. If the patient has a Primary Care Provider at RFGH, please contact that PCP. Otherwise, call (207) 474-5121 and ask to speak to hospitalist.

Contacted provider: _____

FAX RFGH Infusion clinic at 207-858-2404

Contact Infusion Clinic at 207-858-8722

Provider signature _____ Date _____ time _____

If not RFGH credentialed:

Printed name _____ NPI # _____ (required)

RFGH Co-signature _____

Date _____ time: _____

Patient name _____

Date of birth _____

Patient phone number _____

RAVULIZUMAB (Ultomiris) Infusion Order Form

Page 2

PRIOR TO EACH INFUSION:

- Complete Blood Count with Auto Diff (CBC) , Lactic Dehydrogenase (LDH), creatinine (serum), AST, Urinalysis w/Micro/Cult if Indicated.
- Supply patient with the manufacturer/FDA Medication Guide and medication safety card.
- Instruct patient of signs of infusion type reaction and to immediately report chest pain, trouble breathing, or swelling of face, tongue, or throat.
- Assess for infection; delay administration for active infection.

INFUSION

- Will be diluted to 50 mg/ ml in saline.
- Vital signs prior to infusion and every 15 minutes.
- Infuse through a 0.2 or 0.22 micron filter. Flush line with saline after infusion.
- See chart below for maximum infusion rates. Decrease infusion rate for patients experiencing non-allergic infusion reactions. (back pain, muscle spasms, BP changes, rigors, drowsiness.)
- The lower the patient weight, the longer the infusion time that will be required.
- Observe patient for 1 hour after infusion.

Maximum INFUSION RATE:

Weight	Loading dose	Infusion rate	Maintenance dose	Infusion rate
20 to < 30 kg	900 mg	30 mL/hour	2100 mg	30 mL/hour
30 to < 40 kg	1200 mg	48 mL/hour	2700 mg	48 mL/hour
40 to < 60 kg	2400 mg	60 mL/hour	3000 mg	60 mL/hour
60 to < 100 kg	2700 mg	90 mL/hour	3300 mg	90 mL/hour
≤ 100 kg	3000 mg	150 mL/hour	3600 mg	150 mL/hour

Revised: 6/9/25

loc: S:\Lisa Caswell\Physician order forms\Eculizumab (Soliris).docx